1 Landgren O, Kyle RA, Pfeiffer RM, Katzmann JA, Caporaso NE, Hayes RB et al.
Monoclonal gammopathy of undetermined signiﬁcance (MGUS) consistently
precedes multiple myeloma: a prospective study. Blood 2009; 113: 5412–5417.
2 Kyle RA, Therneau TM, Rajkumar SV, Larson DR, Plevak MF, Offord JR et al. Pre-
valence of monoclonal gammopathy of undetermined signiﬁcance. N Engl J Med
2006; 354: 1362–1369.
3 Kyle RA, Therneau TM, Rajkumar SV, Offord JR, Larson DR, Plevak MF et al. A long-
term study of prognosis in monoclonal gammopathy of undetermined
signiﬁcance. N Engl J Med 2002; 346: 564–569.
4 Kristinsson SY, Tang M, Pfeiffer RM, Bjorkholm M, Blimark C, Mellqvist UH et al.
Monoclonal gammopathy of undetermined signiﬁcance and risk of skeletal
fractures: a population-based study. Blood 2010; 116: 2651–2655.
5 Kyle RA, Remstein ED, Therneau TM, Dispenzieri A, Kurtin PJ, Hodneﬁeld JM et al.
Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma.
N Engl J Med 2007; 356: 2582–2590.
6 Greipp P, R Kyle. Clinical, morphological, and cell kinetic differences among
multiple myeloma, monoclonal gammopathy of undetermined signiﬁcance, and
smoldering multiple myeloma. Blood 1983; 62: 166–171.
7 Witzig TE, Timm M, Larson D, Therneau T, Greipp PR. Measurement of apoptosis
and proliferation of bone marrow plasma cells in patients with plasma cell pro-
liferative disorders. Br J Haematol 1999; 104: 131–137.
8 Kyle RA, Durie BG, Rajkumar SV, Landgren O, Blade J, Merlini G et al. Monoclonal
gammopathy of undetermined signiﬁcance (MGUS) and smoldering (asympto-
matic) multiple myeloma: IMWG consensus perspectives risk factors for
progression and guidelines for monitoring and management. Leukemia 2010; 24:
9 Kyle RA, Yee GC, Somerﬁeld MR, Flynn PJ, Halabi S, Jagannath S et al. American
Society of Clinical Oncology 2007 clinical practice guideline update on the role of
bisphosphonates in multiple myeloma. J Clin Oncol 2007; 25: 2464–2472.
10 Terpos E, Sezer O, Croucher PI, Garcia-Sanz R, Boccadoro M, San Miguel J et al. The
use of bisphosphonates in multiple myeloma: recommendations of an expert
panel on behalf of the European Myeloma Network. Ann Oncol 2009; 20:
11 Morgan GJ, Child JA, Gregory WM, Szubert AJ, Cocks K, Bell SE et al. Effects of
zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly
diagnosed multiple myeloma (MRC Myeloma IX): secondary outcomes from a
randomised controlled trial. Lancet Oncol 2011; 12: 743–752.
12 Durie BG, Harousseau JL, Miguel JS, Blade J, Barlogie B, Anderson K et al. Inter-
national uniform response criteria for multiple myeloma. Leukemia 2006; 20:
13 Rajkumar SV, Harousseau JL, Durie B, Anderson KC, Dimopoulos M, Kyle R et al.
Consensus recommendations for the uniform reporting of clinical trials: report
of the International Myeloma Workshop Consensus Panel 1. Blood 2011;
14 Anderson KC, Kyle RA, Rajkumar SV, Stewart AK, Weber D, Richardson P. Clinically
relevant end points and new drug approvals for myeloma. Leukemia 2008; 22:
15 Lan K, DeMets D. Discrete sequential boundaries for clinical-trials. Biometrika
1983; 70: 659–663.
16 Martin A, Garcia-Sanz R, Hernandez J, Blade J, Suquia B, Fernandez-Calvo J et al.
Pamidronate induces bone formation in patients with smouldering or indolent
myeloma, with no signiﬁcant anti-tumour effect. Br J Haematol 2002; 118: 239–242.
17 Musto P, Petrucci MT, Bringhen S, Guglielmelli T, Caravita T, Bongarzoni V et al.
A multicenter, randomized clinical trial comparing zoledronic acid versus obser-
vation in patients with asymptomatic myeloma. Cancer 2008; 113: 1588–1595.
18 D’Arena G, Gobbi PG, Broglia C, Sacchi S, Quarta G, Baldini L et al. Pamidronate
versus observa tion in asymptomati c myeloma: ﬁnal results with long-term follow-
up of a randomized study. Leuk Lymphoma 2011; 52: 771–775.
19 Morgan GJ, Davies FE, Gregory WM, Cocks K, Bell SE, Szubert AJ et al. First-line
treatment with zoledronic acid as compared with clodronic acid in multiple
myeloma (MRC Myeloma IX): a randomised controlled trial. Lancet 2010; 376:
20 Gnant M, Mlineritsch B, Stoeger H, Luschin-Ebengreuth G, Heck D, Menzel C et al.
Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with
early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised
trial. Lancet Oncol 2011; 12: 631–641.
21 Kademani D, Koka S, Lacy MQ, Rajkumar SV. Primary surgical therapy for osteo-
necrosis of the jaw secondary to bisphosphonate therapy. Mayo Clin Proc 2006;
22 Billadeau D, Van Ness B, Kimlinger T, Kyle RA, Therneau TM, Greipp PR et al. Clonal
circulating cells are common in plasma cell proliferative disorders: a comparison
of monoclonal gammopathy of undetermined signiﬁcance, smoldering multiple
myeloma, and active myeloma. Blood 1996; 88: 289–296.
23 Witzig T, Kyle R, O’Fallon W, Greipp P. Detection of peripheral blood plasma cells
as a predictor of disease course in patients with smoldering multiple myeloma. Br
J Haematol 1994; 87: 266–272.
24 Madan S, Kyle RA, Greipp PR. Plasma cell labeling index in the evaluation of
smoldering (asymptomatic) multiple myel oma. Mayo Clin Proc 2010; 85: 300.
25 Blade J, Dimopoulos M, Rosinol L, Rajkumar SV, Kyle RA. Smoldering (asympto-
matic) multiple myeloma: current diagnostic criteria, new predictors of outcome,
and follow-up recommendations. J Clin Oncol 2010; 28: 690–697.
26 Dispenzieri A, Kyle RA, Katzmann JA, Therneau TM, Larson D, Benson J et al.
Immunoglobulin free light chain ratio is an independent risk factor for progres-
sion of smoldering (asymptomatic) multiple myeloma. Blood 2008; 111: 785–789.
27 Mateos M-V, Lopez-Corral L, Hernandez M, Giraldo P, De La Rubia J, de Arriba F
et al. Smoldering multiple myeloma (SMM) at high-risk of progression to symp-
tomatic disease: a phase III, randomized, multicenter trial based on lenalidomide-
dexamethasone (Len-Dex) as induction therapy followed by maintenance therapy
with len alone vs no treatment. ASH Annual Meeting Abstracts 2011; 118 :991.
Thalidomide and zoledronic acid for asymptomatic myeloma
TE Witzig et al
& 2013 Macmillan Publishers Limited Leukemia (2013) 220 – 225